Evidence map›Paper›PMID 42491092›Full record

ArticleFrontiers in immunology2026

Potential effects of genetic variations in fusion protein on the virulence of human respiratory syncytial virus.

Jingjing Song, Na Wang, Zhen Zhu, Naiying Mao, Hai Li, Jinhua Song, Lei Cao, Baicheng Xia, Min Liao, Wuyang Zhu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingjing Song *National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Na Wang *National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Zhen ZhuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Naiying MaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Hai LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jinhua SongNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Lei CaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Baicheng XiaNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Min LiaoKey Laboratory of Animal Virology of Ministry of Agriculture, Zhejiang University, Hangzhou, Zhejiang, China.
Wuyang ZhuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yan ZhangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The fusion glycoprotein (F protein) of human respiratory syncytial virus (HRSV) critically determines viral infectivity and host immune recognition. This study evaluated the effects of F protein genetic variations from the globally dominant HRSV genotypes ON1 and BA9 on viral replication dynamics and pathogenicity. Methods: Using a reverse genetics system, two recombinant HRSV strains, rLong-BJ1903-AF and rLong-SY2103-BF, were generated by replacing the F gene in the isogenic Long-bacterial artificial chromosome (BAC) backbone with F genes derived from the clinical isolates BJ19-03 (ON1 genotype) and SY21-03 (BA9 genotype), respectively. Their phenotypes were assessed in cellular and animal models. Results: Discussion: These findings indicate that both recombinant viruses exhibit reduced replication capacity and less severe pathogenic phenotypes compared with the Long-BAC parental strain in this F-gene replacement system, providing a foundation for antiviral and immunological strategies targeting HRSV.

Indexed as

Genetic VariationRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsViral Fusion ProteinsAnimalsCell LineCytokinesFemaleHumansMiceReverse GeneticsViral LoadVirulenceVirus ReplicationCytokinesF protein, human respiratory syncytial virusViral Fusion Proteinsfusion proteinhuman respiratory syncytial viruspathogenesisreverse geneticsvirulence

Identifiers

PMID42491092
PMCPMC13376264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.